Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S

Journal of Medicinal Chemistry

Volumn 47, Issue 20, 2004, Pages 4799-4801

  Thurmond, Robin L ^a   Beavers, Mary Pat ^a   Cai, Hui ^a   Meduna, Steven P ^a   Gustin, Darin J ^a   Sun, Siquan ^a   Almond, Harold J ^b   Karlsson, Lars ^a   Edwards, James P ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN S; CYSTEINE PROTEINASE INHIBITOR; PEPTIDE;

ARTICLE; CELL ACTIVITY; CHEMICAL STRUCTURE; COVALENT BOND; DATA BASE; DRUG POTENCY; ELECTRONICS; ENZYME INHIBITION; IC 50; INFORMATION PROCESSING;

B-LYMPHOCYTES; CATHEPSINS; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; INHIBITORY CONCENTRATION 50; PEPTIDES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4544321692     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0496133     Document Type: Article

References (18)

1. (a) Villandangos, J. A.; Bryant, R. A. R.; Deussing, J.; Driessen, C.; Lennon-Dumenil, A.-M.; Riese, R. J.; Roth, W.; Saftig, P.; Shi, G.-P. Chapman, H. A.; Peters, C.; Ploegh, H. L. Proteases Involved in MHC Class II Antigen Presentation. Immunol. Rev. 1999, 172, 109-120.
2. (b) Nakagawa, T. Y.; Rudensky, A. Y. The Role of Lysosomal Proteinases in MHC Class II-Mediated Antigen Processing and Presentation. Immunol. Rev. 1999, 172, 121-129.
3. Shi, G.-P.; Webb, A. C.; Foster, K. E.; Knoll, J. H. M.; Lemere, C. A.; Munger, J. S.; Chapman, H. A. Human Cathepsin S: Chromosomal Localization, Gene Structure, and Tissue Distribution. J. Biol. Chem. 1994, 269, 11530-11536.
4. (a) Shi, G.-P.; Villadangos, J. A.; Dranoff, G.; Small, C.; Gu, L.; Haley, K. J.; Riese, R.; Ploegh, H. L.; Chapman, H. A. Cathepsin S. Required for Normal MHC Class II Peptide Loading and Germinal Center Development. Immunity 1999, 10, 197-206.
5. (b) Nakagawa, T. Y.; Brissette, W. H.; Lira, P. D.; Griffiths, R. J.; Petrushova, N.; Stock, J.; McNeish, J. D.; Eastman, S. E.; Howard, E. D.; Clarke, S. R. M.; Rosloniec, E. F.; Elliott, E. A.; Rudensky, A. Y. Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice. Immunity 1999, 10, 207-217.
6. (a) Riese, R. J.; Wolf, P. R.; Bromme, D.; Natkin, L. R.; Villadango, J. A.; Ploegh, H. L.; Chapman, H. A. Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading. Immunity 1996, 4, 357-366.
7. (b) Riese, R. J.; Mitchell, R. N.; Villadangos, J. A.; Shi, G.-P.; Palmer, J. T.; Karp, E. R.; De Sanctis, G. T.; Ploegh, H. L.; Chapman, H. A. Cathepsin S Activity Regulates Antigen Presentation and Immunity. J. Clin. Invest. 1998, 101, 2351-2363.
8. (a) Bromme, D.; Smith, R. A.; Coles, P. J.; Kirschke, H.; Storer, A. C.; Krantz, A. Potent Inactivation of Cathepsins S and L by Peptidyl (Acyloxy)methyl Ketones. Bio. Chem. Hoppe-Seyler 1994, 375, 343-347.
9. (b) Palmer, J. T.; Rasnick, D.; Klaus, J. L.; Bromme, D. Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors. J. Med. Chem. 1995, 38, 3193-3196.
10. (c) Katunuma, N.; Murata, E.; Kakegawa, H.; Matsui, A. Tsuzuki, H.; Tsuge, H.; Turk, D.; Turk, V.; Fukushima, M.; Tada, Y.; Asao, T. Structure Based Development of Novel Specific Inhibitors for Cathepsin L and Cathepsin S In Vitro and In Vivo. FEBS Lett. 1999, 458, 6-10.
11. (d) Ward, Y. D.; Thomson, D. S.; Frye, L. L.; Cywin, C. L.; Morwick, T. Emmanuel, M. J.; Zindell, R.; McNeil, D.; Bekkali, Y.; Giradot, M.; Hrapchak, M.; DeTuri, M.; Crane, K.; White, D.; Pav, S.; Wang, Y.; Hao, M.-H.; Grygon, C. A.; Labadia, M. E.; Freeman, D. M.; Davidson, W.; Hopkins, J. L.; Brown, M. L.; Spero, D. M. Design and Synthesis of Dipeptide Nitriles as Reversible and Potent Cathepsin S Inhibitors. J. Med. Chem. 2002, 45, 5471-5481.
12. (e) Cywin, C. L.; Firestone, R. A.; McNeil, D. W.; Grygon, C. A.; Crane, K. M.; White, D. M.; Kinkade, P. R.; Hopkins, J. L.; Davidson, W.; Labadia, M. E.; Wildeson, J.; Morelock, M. M.; Peterson, J. D.; Raymond, E. L.; Brown, M. L.; Spero, D. M. The Design of Potent Hydrazones and Disulfides as Cathepsin S Inhibitors. Bioorg. Med. Chem. Lett. 2003, 11, 733-740.
13. For a recent review, see: Leroy, V.; Thurairatnam, S. Cathepsin S Inhibitors. Expert Opin. Ther. Pat. 2004, 14, 301-311.
14. (a) Altmann, E.; Renaud, J.; Green, J.; Parley, D.; Cutting, B.; Jahnke, W. Arylaminoethyl Amides as Novel Non-Covalent Cathepsin K Inhibitors. J. Med. Chem. 2002, 45, 2352-2354.
15. (b) Kim, T.-S.; Hague, A. B.; Lee, T. I.; Lian, B.; Tegley, C. M.; Wang, X.; Burgess, T. L.; Qian, Y.-X.; Ross, S.; Tagari, P.; Lin, C.-H.; Mayeda, C.; Dao, J.; Jordan, S.; Mohr, C.; Cheetham, J.; Viswanadhan, V.; Tasker, A. S. (4-Piperidinylphenyl)aminoethyl Amides as a Novel Class of Non-Covalent Cathepsin K Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 87-90.
16. McGrath M. E.; Klaus J. L.; Barnes M. G.; Bromme D. Crystal Structure of Human Cathepsin K Complexed with a Potent Inhibitor. Nat. Struct. Biol. 1997, 4, 105-109.
17. Kuntz, I. D.; Blaney, J. M., Oatley, S. J.; Langridge, R.; Ferrin, T. E. A Geometric Approach to Macromolecule-Ligand Interactions. J. Mol. Biol. 1982, 161, 269-288. The DOCK software suite of programs is available from the University of California, San Francisco, CA. DOCK 4.0 was used for this study.
18. For the pharmacological characterization of a related cathepsin S inhibitor, see: Thurmond, R. L.; Sun, S.; Sehon, C. A.; Baker, S. M.; Cai, H.; Gu, Y.; Jiang, W.; Riley, J. P.; Williams, K. N.; Edwards, J. P.; Karlsson, L. Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor. J. Pharm. Exp. Ther. 2004, 308, 268-276.